CAMPATH-1H [alemtuzumab] compassionate treatment in patients with prolymphocytic leukemia (PLL) who have failed at least one prior regimen and chronic lymphocytic leukemia (CLL) patients who have failed fludarabine therapy.

Trial Profile

CAMPATH-1H [alemtuzumab] compassionate treatment in patients with prolymphocytic leukemia (PLL) who have failed at least one prior regimen and chronic lymphocytic leukemia (CLL) patients who have failed fludarabine therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top